

**Supplementary Material for**

**Title: Spatial organization of single mRNPs at different stages along the gene expression pathway**

Srivathsan Adivarahan<sup>1</sup>, Nathan Livingston<sup>2</sup>, Beth Nicholson<sup>3</sup>, Samir Rahman<sup>1</sup>, Bin Wu<sup>2</sup>, Olivia Rissland<sup>3,4</sup> and Daniel Zenklusen<sup>1\*</sup>

(1) Département de Biochimie et médecine moléculaire, Université de Montréal,  
Montréal, Québec, Canada

(2) Johns Hopkins School of Medicine, Biophysics and Biophysical Chemistry, Center  
for Cell Dynamics, Baltimore, USA

(3) Molecular Medicine Program, The Hospital for Sick Children, Toronto, Canada

(4) Current address: Department of Biochemistry and Molecular Genetics, University of  
Colorado School of Medicine, Aurora, USA

**\*Corresponding author:** [daniel.r.zenklusen@umontreal.ca](mailto:daniel.r.zenklusen@umontreal.ca)

**This document includes:**

Materials and Methods

Figs. S1 to S7

Tables S1 + S2 + S3

## **MATERIALS AND METHODS**

### **Reagents used, stock concentrations, working concentrations and treatment conditions**

Puromycin dihydrochloride (Sigma P8833) – stock at 5 mg/ml in water, Cycloheximide (Sigma C7698-1G) – stock 5 mg/ml in ethanol, Sodium Arsenite (Sigma 35000-1L-R) – stock 50 mM in water, Homoharringtonine (Sigma SML1091-10MG) – stock 10mg/ml in DMSO. The drugs were diluted in warm media to get final working concentrations and cells were treated prior to fixation as follows: Puromycin (100 µg/ml for 10 min), Cycloheximide (100 µg/ml for 10 min), Homoharringtonine – 100µg/ml for 10 mins or 1hr and Sodium Arsenite (2 mM for 1 hour).

### **Cell culture and drug treatment**

HEK293 and U2OS osteosarcoma cell lines were maintained at 37°C and 5% CO<sub>2</sub> in Dulbecco's Modified Eagle Medium (DMEM) (Wisent, 319-005-CL) supplemented with 10% fetal bovine serum (FBS) (Wisent, 080-150) and passaged every 2-3 days with Trypsin (Wisent 325-043-EL). Cells were plated on poly-L-Lysine (Sigma, P8920) coated coverslips the day before treatment and fixation. On the day of the experiment, media was replaced with fresh warm media containing drug in indicated concentrations and placed back in the incubator. After treatment, the cells were briefly washed with 1xPBS, fixed with 4% paraformaldehyde in 1xPBS (pH 7.4) for 10 minutes at room temperature, washed three times with 1xPBS and stored overnight in 70% ethanol at -20°C for permeabilization. Alternatively, the cells were permeabilized using 0.1% TritonX-100 + 0.5%BSA in 1x PBS for 15mins after which they were washed 2 times with 1x PBS for 5 mins each immediately before using the samples for smFISH.

**Plasmid Preparation:** The phage-ubc-flag-24xSunTag-Fluc-oxBFP-AID-baUTR-24xMS2 plasmid was prepared as described in (1).

## **Generation and screening of EIF4G1 and PABPC1 mutant cell lines**

Mutant cell lines were generated using CRISPR-Cas9. To produce sgRNAs targeting either EIF4G1 or PABPC1, annealed DNA oligos (Table S1) were ligated into the BbsI site of plasmid pX330 (Ran 2013). Homology repair constructs containing the intended mutations and upstream and downstream homology arms (~1 kb in total) were ligated into the plasmid Lox-Stop-Lox-TOPO- $\Delta$  stop (Rakheja 2014), in which homology arms are cloned surrounding a puromycin resistance cassette flanked by loxP sites (Table S1).

HEK293 cells ( $5 \times 10^5$  cells in one well of a 6-well plate) were transfected with 250 ng of the pX330-sgRNA construct and 1  $\mu$ g of the repair construct using Lipofectamine 2000 according to the manufacturer instructions, and then incubated in EMEM supplemented with 10% FBS in a humidified incubator at 37° C with 5% CO<sub>2</sub>. Two days following transfection, cells were trypsinized and 10% of the cells were moved into a 15-cm dish. After 24 h, puromycin was added to a final concentration of 3  $\mu$ g/mL, and the media was changed daily for the next 3 days. The following day, single cells were seeded into each well of a 96-well plate on a MoFlo Astrios cell sorter (Beckman Coulter) at the Flow and Mass Cytometry Facility at SickKids Hospital, Toronto. Following expansion of single colonies, cells were harvested and screened by PCR using primers that anneal to the genome outside of the homology arm region (Table S1). To excise the puromycin resistance cassette from positive clones, the cells were transfected with 1  $\mu$ g of pgk-Cre (2) and incubated for 3 days before single-cell seeding, expansion, and screening for loss of the puromycin

resistance gene by PCR as described above. The PCR products were analyzed by Sanger sequencing to ensure that the intended mutations were present.

### **Cell viability assays**

Cell viability was measured using PrestoBlue Cell Viability Reagent (Invitrogen) according to the manufacturer's instructions. Briefly, cells were seeded in triplicate in 96-well plates at 1000 cells per well in 90  $\mu$ L of EMEM supplemented with 10% FBS, and then incubated at 37° C with 5% CO<sub>2</sub>. At 24 h, 48 h, and 72 h after seeding, 10  $\mu$ L of PrestoBlue reagent was added to each well. After a further 6.5-h incubation at 37°C with 5% CO<sub>2</sub>, the fluorescence of each well was read on a SpectraMax M2 microplate reader (Molecular Devices).

### **Polysome profiling**

To generate polysome profiles, cycloheximide was added to cells in a 10-cm dish to a final concentration of 100  $\mu$ g/mL, and the cells were incubated for 10 min at 37°C. The cells were then placed on ice and washed twice with ice-cold PBS containing 100  $\mu$ g/mL cycloheximide. Cells were lysed by shearing four times through a 26-gauge needle in 500  $\mu$ L of lysis buffer (10 mM Tris-HCl pH 7.4, 5 mM MgCl<sub>2</sub>, 100 mM KCl, 1% Triton X-100, 2 mM DTT, 500 U/ml Rnasin (Promega), EDTA-free protease inhibitor cocktail (Sigma), 100  $\mu$ g/mL cycloheximide). Following centrifugation at 1300  $\times$  g for 10 min at 4°C, the supernatant was collected, flash frozen in liquid nitrogen, and stored at -80°C until further processing.

Lysates were separated by loading 300  $\mu$ L onto a 10-50% (w/v) sucrose gradient prepared with a Gradient Master (BioComp Instruments) and centrifuging for 2 h at 36,000 rpm in a SW41Ti rotor (Beckman Coulter) at 4° C. Gradients were fractionated on a Piston Gradient Fractionator

(BioComp) coupled to a EM-1 Econo UV detector (Bio-Rad). UV profile data were recorded using Gradient Profiler software v 2.07 (BioComp).

### **smRNA FISH**

Custom DNA probe sets were designed using Stellaris<sup>®</sup> Probe Designer, synthesized by Biosearch Technologies containing 3' amine reactive group and labeled with far red dye Cy5 (GEPA25001), red dyes Cy3 (GEPA23001) from Sigma or Dylight 550 (Thermo Scientific 62263) or green dye Dy488 (Thermo Scientific 46403) as described in (3). Probe sequences are shown in Table S2. Probe combination used are shown in Table S3. smFISH was done as described in (4). Prior to hybridization, cells were rehydrated in 1xPBS, then washed with 10% formamide/2xSSC for 10 minutes at room temperature. The cells were hybridized with 10-20 ng of each probe mix plus 40 µg of ssDNA/tRNA resuspended in the hybridization solution (10% dextran sulfate/10% formamide/2xSSC/2 mM VRC/0.1 mg/ml BSA) for 3 hours in the dark at 37°C. Post hybridization washes (2x 30 min) were carried out at 37°C with 10% formamide/2xSSC. Samples were then rinsed with 1xPBS and mounted with ProLong Gold antifade reagent with DAPI (P36935, Invitrogen).

### **Image Acquisition and pixel shift correction**

Images were acquired with a 63x NA 1.46 oil objective on a Zeiss Elyra PS.1 system equipped with an Andor EMCCD iXon3 DU-885 CSO VP461 camera (1004x1002 pixels), the following filter sets: DAPI: BP420-480 + LP750 (Zeiss SR cube 07), Cy2: BP495-590+LP750 (Zeiss SR cube 13), Cy3: LP570 (Zeiss SR cube 14), Cy5: LP655 (Zeiss SR cube 10) and the following lasers: 50 mW 405 nm HR diode, 100 mW 488 nm HR diode, 100 mW 561 nm HR DPSS, 150 mW 642 nm HR diode. Each image was acquired using 3 rotations and a grid size of 42 µm for all

channels. The microscope was located in a temperature-controlled room and samples were kept in the room for at least an hour before imaging to minimize thermal fluctuations. To correct for pixel shifts between channels, 0.1  $\mu\text{m}$  TetraSpec beads (Invitrogen T-7279) were imaged in all channels, and the channel shift values and chromatic aberration were calculated and corrected using the built-in channel alignment tool in ZEN 2012 SP5 which uses an affine image alignment algorithm and later applied to the images. This correction was calculated for each day of imaging.

### **RNA spot detection, spot assignment and distance measurements**

For image analysis, 3D datasets were reduced to 2D data using maximum projections in FiJi. Spot detection was done by 2D Gaussian fitting as described in (5, 6). For 3D analysis, the spots were detected using AIRLOCALIZE as described in (7). To separate cytoplasmic and nuclear mRNPs, masks were created in FiJi by manual segmentation using DAPI stained nuclei as reference, while ensuring that regions with overlapping spots within the same channel were not included. Assignment of the 5', 3' and/or the mid spots to either the cytoplasmic or the nuclear masks was done using MATLAB (MathWorks). To measure distances between different regions of mRNPs, spots from different channels were first grouped to assign neighboring spots corresponding a single RNA. This was achieved by using spots from one channel as a reference and finding spots from the other channels within a defined radius using the coordinates from 2D Gaussian fitting or 3D Gaussian fitting using a custom MATLAB script. 300nm for 2D analysis and 400nm for 3D analysis were chosen as radii to limit assigning signals from neighboring RNAs. Groups with more than one spot from each channel, which could correspond to overlapping mRNPs or mRNPs close together in space, were discarded. For 2 color imaging, the 5' signal was taken as reference and for 3 color imaging, the middle was taken as reference. Switching references yielded comparable

results (not shown). 2D or 3D distances between different regions of the mRNPs were then calculated for each signal within a group.

### **Combined smFISH and Immunofluorescence for simultaneous detection of mRNA conformation and nascent translation**

Human U2OS osteosarcoma cell line (American Type Culture Collection HTB-96) expressing stdMCP-HaloTag, phR-scFV-GCN4-sfGFP-GB1-NLS-dWPRE, and pBabe-TIR1-9myc was prepared as described in (1). Single-molecule FISH immunofluorescence was performed as described in (1, 8). In brief, cells were plated on 18mm diameter, 0.13mm thick collagen coated coverslips (Fisher) in a 12-well dish. Cells were then transfected with 250 ng of the phage-ubc-flag-24xSunTag-Fluc-oxBFP-AID-baUTR-24xMS2 construct using X-tremeGENE 9 transfection reagent (XTG9-RO ROCHE). Six hours after transfection, IAA (Sigma-Aldrich) was added to a final concentration of 250  $\mu$ M. 20 hours after transfection, fresh IAA was added to a final concentration of 250  $\mu$ M. 24 hours after transfection, cells were fixed for 10 minutes in PBS + 5 mM MgCl<sub>2</sub> (PBSM), permeabilized for 15 minutes in PBSM + 0.1% Triton-X and 0.5 % BSA, and incubated with 100 nM MS2v5-Cy5 and 50 nM SunTagV4-Qusar 570 smFISH probe sets (Table S2) and primary antibody against GFP (GFP-1010, Aves labs, Inc.) and incubated for three hours at 37°C. After washing, cells were incubated with Alexa Fluor 488 labeled secondary antibody (ThermoFischer) and mounted in ProLong Diamond antifade reagent with DAPI (Life Technologies). Images were acquired on a custom inverted wide-field Nikon Eclipse Ti-E microscope equipped with three Andor iXon DU897 EMCCD cameras (512x512 pixels), Apochromatic TIRF 100X Oil Immersion Objective Lens/1.49 NA (Nikon MRD01991), encoded Stage with 150 micron Piezo Z (ASI), and LU-n4 four laser unit with solid state 405 nm, 488 nm, 561 nm, and 640 nm lasers (Nikon), a TRF89901-EM ET-405/488/561/640nm Laser Quad Band



Filter Set for TIRF applications (Chroma), and Nikon H-TIRF system. Images were acquired using in-unit intermediate 1.5x magnification changer for a final magnification of 150x and independent, epi-illumination from the 488, 561, and 640 nm lasers. Image pixel size: XY, 106.7 nm; Z-step, 200 nm. A total of 29 cells without drug treatment (total of individual 397 mRNAs) and 40 cells (98 individual mRNAs) upon puromycin treatment we analyzed.

### **Combined smFISH and Immunofluorescence Data Analysis**

All image analysis was performed using existing or custom build packages in MatLab (MathWorks). Gaussian fitting of smFISH and immunofluorescence spot intensities was performed using FISH-quant (9). Briefly, cytoplasmic FISH spots were fit to a 3D Gaussian to determine the mRNA and translation site coordinates in each color. Both 5'-end, 3'-end, and translation site intensities were detected independently by this method. Image registration was performed by imaging 100 nm TetraSpeck Microspheres (ThermoFisher) and calibrating the field correction based on an affine transformation in a custom built MatLab package. The transformation matrix was first verified for reproducibility on other microsphere samples and then applied to mRNA samples (data not shown). Only 2D distances were considered for this analysis. To determine the end-to-end mRNA distance, we first assigned the Quasar 570 channel (SunTag Probes) to FITC channel (Alexa 488 labeled translation site) by setting a colocalization threshold of 300 nm after image correction. We then assigned the Quasar 570 to Cy5 (MS2 Probes), again with a colocalization threshold of 300 nm. We first grouped mRNA with both Cy3 and Cy5 colocalization, and then determined if there was also a colocalized translation site signal. We then binned two-color mRNA based on the presence (translating) or absence (non-translating) of translation site signal. We then determined the end-to-end distance, and, in the case of the translating mRNAs, the associated translation site intensity.

## Data Plotting

All measurements were made for at least 2 independent biological replicates and the data plotted are representative from one of the replicates. For each measurement, at least 5 different fields were imaged with each image containing a minimum of 10 cells to make a total of at least 50 cells. A minimum of 593 RNAs were considered for cytoplasmic plots and a minimum of 430 RNAs were considered for the nuclear plots, unless mentioned otherwise. The center of mass plots in Fig. 1G, 2D, 4D were made using R. The center of mass was calculated as the mean of the coordinates of the three regions. The different conformations were then aligned using their center of masses. For the 3-color scatter plot in Fig. 2E, 4E, S5 and S7, to get a pair of co-localization precision values, two values were chosen randomly from our data. These values were taken as the X and Y coordinates for the scatter plot. The values that served as the X and Y coordinates were used to get density plots in the same figure. The mean Radius of gyration ( $\langle R_g \rangle$ ) was calculated using:

$$\langle R_g \rangle = \sqrt{\frac{1}{3} \sum_{k=1}^3 (r_k - r_{mean})^2}$$


where k represents one of the three regions of the mRNP and  $r_k$  the position of the corresponding position in space as determined by 2D Gaussian fitting.

## Immunoprecipitations and western blotting

Cells were washed with 1X PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na<sub>2</sub>HPO<sub>4</sub>, 1.47 mM KH<sub>2</sub>PO<sub>4</sub>, pH 7.4) and then lysed with 1 ml ice-cold lysis buffer A (100 mM KCl, 0.1 mM EDTA, 20 mM HEPES, pH 7.6, 0.4% NP-40, 10% glycerol, with freshly added 1 mM DTT and complete


mini EDTA-free protease inhibitors [Roche; one tablet per 25 ml lysis buffer]) per 2.5 million cells. 50  $\mu$ l was saved as the input sample. Cells were incubated with antibody (diluted according to manufacturer's instructions) for 2 hours, rotating at 4°C.  $\alpha$ -PABPC1 antibody was purchased from Abcam (ab21060), and  $\alpha$ -eIF4G1 from MBL International. EZ view protein G Sepharose (Sigma) was washed twice with lysis buffer and added to lysate with 40  $\mu$ l slurry used per ml of lysate. The beads and lysate were incubated with the lysate for an additional hour rotating at 4°C. The beads were washed 3X with cold lysis buffer. After the first wash, the beads were transferred to a new tube. The beads were then resuspended in protein loading dye (Life Technologies) with freshly added reducing agent, according to manufacturer's instructions, and boiled for 3 min. 2% lysate and 10% immunoprecipitants were loaded onto an SDS-PAGE gel and probed for PABPC1 and eIF4G1.  $\alpha$ -PABPC1 and  $\alpha$ -eIF4G1 were used at 1:1000, and  $\alpha$ -rabbit IgG HRP (at 1:10,000) was used as the secondary antibody.

## Supplementary Figures




Adivarahan et al. Figure S1

**Figure S1: Positions of smFISH probes used in this study.** Cartoons illustrating the positions of the probes used for the different genes used. See Supplemental Table 1 for probe sequences. The transcripts sequences were obtained from ensembl – MDN1 (ENST00000369393), POLA1 (ENST00000379068), PRPF8 (ENST00000304992), TUG1 (ENST00000644773) and OIP5-AS1 (ENST00000500949)




Adivarahan et al. Figure S2

**Figure S2: 5'-3' distances measured in 2D and 3D and upon treatment with translation inhibitors** (A) Cartoon illustrating how 2D projection alters 5'-3' distances measured (above) and violin plots showing distance distribution of co-localization precision and 5'-3' distances for MDN1 mRNAs calculated in 2D and 3D. Dotted line delineates the percentage of MDN1 mRNA with 5'-3' distances less than 50nm. (B) Violin plots showing distance distribution of co-localization precision and 5'-3' distances for MDN1 mRNAs in cells permeabilized with either Ethanol or TritonX-100, (C) Violin plots showing distance distribution of co-localization precision and 5'-3' distances for MDN1 mRNAs determined by Gaussian fitting from untreated and homoharringtonine (1hr) treated cells.




Adivarahan et al. Figure S3

**Figure S3: Visualizing mRNP conformation of single POLA1, PRPF8 and MDN1 mRNAs.** (A and B) smFISH images using probes hybridizing to the 5' and 3' ends of PRPF8 and POLA1 mRNAs in paraformaldehyde fixed HEK293 cells, either untreated (A) or treated with puromycin (10 min, 100  $\mu$ g/ml) (B). (C) smFISH using 5' (red), 3' (green), and tiling (cyan) for MDN1 mRNA in paraformaldehyde fixed HEK293 cells treated with puromycin (10 min, 100  $\mu$ g/ml). Nuclei are visualized by DAPI staining (grey). Magnified images of individual RNAs marked by dashed squares are shown on the right. Scale bars, 500 nm.



Adivarahan et al. Figure S4


**Figure S4: Close fraction of mRNP 5'-3' distances are not a result of eIF4G-PABPC1 interaction.** (A) Doubling time for eIF4G1 CRISPR-edited lines. Shown are the doubling times calculated for three independent biological replicates for two independent wild-type and mutant eIF4G1 lines. (B) As in (A), except for PABPC1 CRISPR-edited lines. (C–F) Polysome profiles for wild-type eIF4G1 (C), wild-type PABPC1 (D), mutant eIF4G1 (E), and mutant PABPC1 (F) lines.



Adivarahan et al. Figure S5


**Figure S5: Compaction of the 5' end is altered upon a pulsed homoharringtonine treatment for 10min.** Scatter plot showing 5'- mid and mid-3' distances for individual cytoplasmic MDN1 mRNAs from untreated cells (black) and cells treated with homoharringtonine (100 $\mu$ g/ml, 10min) (red). Frequency distribution are shown on top and on the right.





Adivarahan et al. Figure S6

**Figure S6: mRNA and lncRNA compaction and accumulation in stress granules.** smFISH visualizing 5' and 3' ends of PRPF8 and POLA1 mRNAs (A) or TUG1 and OIP5-AS1 lncRNAs (B) in U2OS cells treated with arsenite (1 hour, 2 mM). Only a selected cytoplasmic region of cells is shown. Stress granules are visualized using an oligo dT probe (grey). Magnified images of individual RNAs localized inside or outside of stress granules are shown on the bottom of the images. For POLA1 and OIP5-AS1, not all magnified single RNAs shown in the bottom are from the corresponding image above. Scale bars, 500 nm.



Adivarahan et al. Figure S7

**Figure S7: Compaction of nuclear MDN1 mRNA is not altered upon puromycin or homoharringtonine treatment. (Left)** Scatter plot showing 5'- mid and mid-3' distances for individual nuclear MDN1 mRNAs from untreated cells (black) and cells treated with puromycin (100µg/ml, 10min) (red). Co-localization precision is shown in grey. Frequency distribution are shown on top and on the right. **(Right)** Violin plots showing distance distribution of co-localization precision and 5'-3' distances for MDN1 mRNAs determined by Gaussian fitting from untreated, puromycin (100µg/ml, 10min) or homoharringtonine (100µg/ml, 1 hour) treated HEK293 cells. White box plot inside the violin plot shows first quartile, median and third quartile. Median distances are shown on the right.

## Tables

**Table S1:** Primers used for making CRISPR/Cas9 cells lines

Name	Sequence (5'-3')	Purpose
PABPC1 M161A gRNA 1 Fw	CACCGAATCTGTTAGCCATCTAAC C	Guide RNA targeting PABPC1; annealed and ligated into pX330
PABPC1 M161A gRNA 1 Rev	AAACGGTTAGATGGCTAACAGAT T C	
PABPC1 region Fw NotI	GCGCACTAGCGGCCGCGAGGAAG CGTTCAACTGTGA	To amplify 5' arm region of PABPC1
PABPC1 Not I 5' arm Rev guide 1 XhoI	GCGCACTAGCGGCCGCCTCGAGA CCTGGATATTTGTGAAATAAAG	
PABPC1 BamHI 3' arm Fw guide 1	CGCGGATCCTAGATGGCTAACAG ATTGTCTCTC	To amplify 3' arm region of PABPC1
PABPC1 region Rev BamHI	CGCGGATCCTTGGTCAGGCTGGTC TCAA	
PABPC1 mutation Fw	GAAAGAGCTATTGAAAAAATGAA TGGAGCGCTCCTAAATGATCGCA AAGTATTTGTTGG	Internal primers for stitch PCR to make PABPC1 mutation
PABPC1 mutation Rev	CCAACAAATACTTTGCGATCATT AGGAGCGCTCCATTCATTTTTTCA ATAGCTCTTTC	
PABPC1 region Fw	GGCGAGAGATTGCGTCAAGAA	Screening for puromycin cassette insertion/excision
PABPC1 region Rev	CCCTGGTAACAGGCATTTGTGAG	
PABP seq Fw1	GCAATATGGAATTCTTTTATATG	To sequence PCR products from PABPC1 mutant cell line screening
PABP seq Fw2	GGAAGTGTGCAGTAATGGATATC	
PABP seq Rev1	CAATCTTGTCGCCCAGACTGG	
eIF4G1 mutant gRNA 1 Fw	CACCGTGCTGCTGGGACATTGTGC	Guide RNA targeting eIF4G1; annealed and ligated into pX330
eIF4G1 mutant gRNA 1 Rev	AAACGCACAATGTCCCAGCAGCA C	
eIF4G1 5' HR Arm Fw NotI	GCGCACTAGCGGCCGC GAGACAGGAAGTAGACTCAAG	To amplify 5' arm region of eIF4G1
eIF4G1 5' HR Arm Rev NotI XhoI	GCGCACTAGCGGCCGC CTCGAG CAATGTCCCAGCAGCACCTGACC	
eIF4G1 3' HR Arm Fw BamHI	CGC GGATCC TGCCGGAAAGAGCAGTACTTG	To amplify 3' arm region of eIF4G1
eIF4G1 3' HR Arm Rev BamHI	CGC GGATCC GGCACCTATTCTGGGCACC	
eIF4G1 mutation Fw	TGCAGCCGCTGCCGCGGGAGCAA TCTGGGGTGGCTGGTTC	Internal primers for stitch PCR to make eIF4G1 mutation
eIF4G1 mutation Rev	CGCCAGTGGGAAACTGCTGCACCCCTTGG GCTGGATAGTAGG	

eIF4G1 region Fw	GTAGTCGCACAGTCTTGGCTC	Screening for puromycin cassette insertion/excision
eIF4G1 region Rev	GAGTCCAGGGCAGAACAGAC	
4G seq Rev1	CACCCCTCGTAGGCAGGCACTC	To sequence PCR products from eIF4G mutant cell line screening
4G seq Fw 1	CAGAGTATGTGTGTACATGTTG	
4G seq Rev2	CTTCCTCGCTAGGCACTTCAG	
4G seq Rev 3	CCAGCAGTCCCCAAGTCAGTGG	

**Table S2:** List of probes used

MDN1 5'	tcgttcttggtcgattaa	POLA1 3'	tgtacagggactgtcagaa
MDN1 5'	taaggtactcaggacacact	POLA1 3'	taccggtaaagcacagctg
MDN1 5'	cacagtacagtcttatcca	POLA1 3'	gtgcacactccgcatcaaaa
MDN1 5'	agcaaatccaaaaggagagg	POLA1 3'	tctcatgatcggtagtaagt
MDN1 5'	ttgaaagactgggatgtgt	POLA1 3'	ctgtagtctgcagaacttt
MDN1 5'	gcatctgaactctctaggaa	POLA1 3'	ctctgctgtgttcttgagtt
MDN1 5'	gtgctcttcattacacagg	POLA1 3'	tagccacttcgggacaagaa
MDN1 5'	cctcaacctgaaatggatca	POLA1 3'	tttgctcagattcactcgg
MDN1 5'	aaaaccaaggccttctccaa	POLA1 3'	ttaggatttcacggcacaac
MDN1 5'	aaaggagacttctggattg	POLA1 3'	cttggttactcctgggattc
MDN1 5'	tcagacgaacaagatgtcc	POLA1 3'	ggaagctgggattttcaac
MDN1 5'	accgacacataagactaag	POLA1 3'	caagggagaaacagatgctg
MDN1 5'	gaagacttttcagacagac	POLA1 3'	acacaacatgagacacagt
MDN1 5'	acagcattctgagaagcaac	POLA1 3'	gactcaacattttgcagcc
MDN1 5'	tcctattggtccttccaaca	POLA1 3'	ctcagaaccgggtcttcag
MDN1 5'	cctgtcactgcagctaaata	POLA1 3'	gctactctcaatccaagtag
MDN1 5'	aagctggactttgagaagct	POLA1 3'	gcctggggtcacttacattc
MDN1 5'	acatctgtgcagcgatacat	POLA1 3'	cataggctaaaggccctgag
MDN1 5'	atatectccagaaggatcca	POLA1 3'	ttcagtcaggctctgagaag
MDN1 5'	aagagctctccattctccaa	POLA1 3'	tgaaaaagcaaacgtcagc
MDN1 5'	aaatccaggtgccatttca	POLA1 3'	ttagaccgggttaattggc
MDN1 5'	caactacccccgcaggaaag	POLA1 3'	actcctggatggctggagaa
MDN1 5'	agcaagaagtgtccatgac	POLA1 3'	agacaagactgaaaaggaca
MDN1 5'	caagaacctgcccactcac	POLA1 3'	agtgcgaaggcttctaaatct
MDN1 5'	cgatcttgaggtgtccacac	POLA1 3'	gagcaattcaacaacaagc
MDN1 5'	aatggcttcggcattccttt	POLA1 3'	cagtgtgtgtctgttgact
MDN1 5'	gttcacatgagatcatggttg	POLA1 3'	atgtgagtgtaaaacacctg
MDN1 5'	gtttgctcatcgacacacat	POLA1 3'	gcactttctatttaaggggc
MDN1 5'	gacatcaggatggttaccaa	POLA1 3'	ccctacacatgttaatggat
MDN1 5'	aatatctcagggcaaacggg	POLA1 3'	tgaatacaacacagtgatecc
MDN1 5'	tacgtccatagcgtactgga	POLA1 3'	ggccaattaagcatccctct
MDN1 5'	gcagaaactgaaggctgct	POLA1 3'	agaaaaaatagcaagcgcc
MDN1 5'	cggaacacagactgctcctg	POLA1 3'	agacggctcctattgtgaaga
MDN1 5'	aagggtgcatggcttctgag	POLA1 3'	aaatacattttgctgctgcc
MDN1 5'	acaattggctgtataccagc	POLA1 3'	agagaggaagactgccata
MDN1 5'	acaccacaacagctgtcac	POLA1 3'	cagcataaattgtacaagggg
MDN1 5'	tcttactgtcagtctgatct	POLA1 3'	agaagaaggcacaacatact
MDN1 5'	gaagaactcctattaccacc	POLA1 5'	aactccctgaatctgacaga

MDN1 5'	ctgccacacaaactctccag	POLA1 5'	ttgattttttctcgccgg
MDN1 5'	cagaaaccacgtctaagggg	POLA1 5'	tttctagggcttctggcgc
MDN1 5'	caatttcctccacagctcaa	POLA1 5'	ccagcttttagccttttcag
MDN1 middle	aagcagcaagattgaccaca	POLA1 5'	taaacacctgtgaagtctc
MDN1 middle	ggactagtgcatacacaagt	POLA1 5'	cctgaaccagcttccaatac
MDN1 middle	actggcatcagacaccattc	POLA1 5'	caatccagtcatactctgg
MDN1 middle	accgcagagaacctaaagtc	POLA1 5'	ggcatcatcttcaaggctat
MDN1 middle	ggcatctacttttactgtgt	POLA1 5'	tctgtctttattgcgtgct
MDN1 middle	tgcaatggagggcaagaag	POLA1 5'	cactgcgagcttcttaccat
MDN1 middle	ctggtggaccagatgtttta	POLA1 5'	tctgcagttttcttccagc
MDN1 middle	aattcatcagaagtcggggg	POLA1 5'	accatcctggacaagtcta
MDN1 middle	ctgagacagtctgaactct	POLA1 5'	cctgtagaatgacacctagc
MDN1 middle	tcccagacaattctgaata	POLA1 5'	tcagtatcattacaggtggt
MDN1 middle	cttctttataccagcgaagc	POLA1 5'	tgaagctccaatggatcttt
MDN1 middle	aaacggctgcccaggaact	POLA1 5'	tgtgcacagagaaaggattc
MDN1 middle	ccaccagcttgctcttaaaa	POLA1 5'	gggaagcaattttctctgaa
MDN1 middle	ggaccttcagttgtgaaaaa	POLA1 5'	agttaatggaggctcctttc
MDN1 middle	ctgatggcaaggactttgtt	POLA1 5'	cagcacgtttaagaggaaca
MDN1 middle	agacggtaatgtcttctcg	POLA1 5'	tctcgacctgtacatcatcg
MDN1 middle	ccactgagaagcaaccactt	POLA1 5'	tgactcctgctcttctctg
MDN1 middle	cttgcaggagacttttcttt	POLA1 5'	ggctcatcaaaagtcaccatc
MDN1 middle	atctgctctgaggatcagtc	POLA1 5'	agccataggctccaggtcca
MDN1 middle	ttcatctaggctgacatctt	POLA1 5'	tctctttgtcccaagccttg
MDN1 middle	ctgagcatgcacaaaattct	POLA1 5'	ttgtttcactctctctgctg
MDN1 middle	cctttggcttccagttctaa	POLA1 5'	agtaggacacggctccctttc
MDN1 middle	ctccagaaaaccaagtgaga	POLA1 5'	catccgggagaaaacttctct
MDN1 middle	aggaagcttcatcatgcttt	POLA1 5'	tgatcaatgtccaacaaga
MDN1 middle	gtcaagtctggatgggacag	POLA1 5'	tgcactgagaaaactgctatc
MDN1 middle	tctgtgtgaggtgattacg	POLA1 5'	gactggaatccactgaaact
MDN1 middle	attgcaggccacaactgaac	POLA1 5'	gccccctttaccaatgggag
MDN1 middle	ttgtaccgcaaagcatag	POLA1 5'	agtggaaatactgttctca
MDN1 middle	gtgccataaaatcagctgtc	POLA1 5'	ggttggtgtactgatcctc
MDN1 middle	ctgcattctctgagacaagc	POLA1 5'	ctcggctgattcaatccaaa
MDN1 middle	tttatctggggtgtgtgatt	POLA1 5'	atgacacaacagctcacatg
MDN1 middle	agatgaggtgacttatctcc	POLA1 5'	agcgttcgctcgatattttt
MDN1 middle	acaggtgtgtgataagaca	POLA1 5'	gtttctttccccgtatttag
MDN1 middle	atctcgaagctcttgaggtg	POLA1 5'	gcatagttctttccactgg
MDN1 middle	tgatgatgcagcaaggacca	POLA1 5'	ctggacatcaggtatctca
MDN1 middle	aatttctcaggagacacct	POLA1 5'	aatcttgaggaagctgtggc
MDN1 middle	ataactcggaccacaaagat	POLA1 5'	agatgtgtgtgcccacaata
MDN1 middle	agtactgctccagaaagaca	OIP5-AS1 5'	acgggaaagtaactgggtaa

MDN1 middle	agfacctctggatttgggtc	OIP5-AS1 5'	gaagtgatagccacatttca
MDN1 middle	ggcaaagggttccacattag	OIP5-AS1 5'	ccaaatcatggaggtaatgt
MDN1 middle	tccaaaacagacttgggtgc	OIP5-AS1 5'	aagaaaagtggcctttcca
MDN1 middle	tgggtctattgagattgccg	OIP5-AS1 5'	ctctctgtgtgaattga
MDN1 middle	tcaaagcagcacttagagaa	OIP5-AS1 5'	agcaggataactggaatcct
MDN1 middle	tctccagctgctggtaaga	OIP5-AS1 5'	cttcttctcctggagatg
MDN1 3'	aagtctcactttggactctt	OIP5-AS1 5'	agcaaaagaccatgtgagt
MDN1 3'	aatgtgaccttctgaccaca	OIP5-AS1 5'	agccttctgcttgcAAAatg
MDN1 3'	aaaaggggagcacttgggtaa	OIP5-AS1 5'	gcacctgtttcaaatgaaac
MDN1 3'	agcattctgtaggctgtaag	OIP5-AS1 5'	attcacaataaccaccctt
MDN1 3'	tggataaaaacctcagccc	OIP5-AS1 5'	cttcttagtcttcttctt
MDN1 3'	actcttctctagttagcagt	OIP5-AS1 5'	ccctgaagtcattcactt
MDN1 3'	cttccaaggcagggagaag	OIP5-AS1 5'	gtggctgaaactggaagaca
MDN1 3'	aagaaaacaggcagctgggc	OIP5-AS1 5'	ctcaactgtgcttatcatgg
MDN1 3'	acaaggactgtcagagctcc	OIP5-AS1 5'	atttggaaattactgctgca
MDN1 3'	aaaagggcagctcccttag	OIP5-AS1 5'	ttttagtatcttcacgtca
MDN1 3'	gcaaggcagagcttagaaca	OIP5-AS1 5'	caggatgagccaggatgtaa
MDN1 3'	ttgggcacacactatgggc	OIP5-AS1 5'	gttctattcagtaaactca
MDN1 3'	ctgtcttggccacttgacag	OIP5-AS1 5'	ttttgtttaaattgggcct
MDN1 3'	cctcactctccagaaacg	OIP5-AS1 5'	aactcctctatgtccaaagt
MDN1 3'	tctaagagaaggtagtctct	OIP5-AS1 5'	ggaaaattctctcactctcc
MDN1 3'	ctataatgtccagttgcttt	OIP5-AS1 5'	catgagggtttttgcttct
MDN1 3'	ttttatagatgacctgggc	OIP5-AS1 5'	caccataaagtcatgatggca
MDN1 3'	ttttacacagcccaaggat	OIP5-AS1 5'	gggttcaggaagagttaat
MDN1 3'	gaggatactgaaaagccact	OIP5-AS1 5'	caaacatccaagtatccacc
MDN1 3'	cattgcatagtctcccgaag	OIP5-AS1 5'	cctttcagcctagaatca
MDN1 3'	ataaaggggcaatcaccttc	OIP5-AS1 5'	ctggggaaagtacctgagtc
MDN1 3'	tacaacaacagggaccatgg	OIP5-AS1 5'	tgatgagaaagttcagtcct
MDN1 3'	agtgtgaggaatcactcttc	OIP5-AS1 5'	tgggaacattgcttctgagg
MDN1 3'	tggctcagctcagcttga	OIP5-AS1 5'	cacgatgaccaaccacaag
MDN1 3'	cgttcttcccagaatgag	OIP5-AS1 5'	ttctatttgaggttcttt
MDN1 3'	atagatggagctgctgagtt	OIP5-AS1 5'	ttctacgacagtctgttctt
MDN1 3'	atcagtttcttgcactgga	OIP5-AS1 5'	gctgatttggaaagcaagac
MDN1 3'	ggccaagtaaaaactgccta	OIP5-AS1 5'	acaatacatacaatgtctct
MDN1 3'	caagtattcagcactgcttt	OIP5-AS1 3'	accacagatctgtcagtatt
MDN1 3'	agtagaacagacacacagt	OIP5-AS1 3'	gccaaacctcaaggataa
MDN1 3'	atcatgacatactgcttaca	OIP5-AS1 3'	gctttagcaagaaattgca
MDN1 3'	tcgacagcttcacagtgtaa	OIP5-AS1 3'	aagtttctctgtttaacct
MDN1 3'	atctgtgtctttgatgacca	OIP5-AS1 3'	gcaaggattttctcttagtg
MDN1 3'	tacatgcttgggacacttg	OIP5-AS1 3'	gcaaggattttctctattg

MDN1 3'	aagatcagtccecctagcata	OIP5-AS1 3'	gtcaggaattttctcaagga
MDN1 3'	ctgactgactgatccagcag	OIP5-AS1 3'	gtcacaatcactgtactt
MDN1 3'	gcacagcatcaactagtaac	OIP5-AS1 3'	tgaatgccattttacgtca
MDN1 3'	gaagtaggaggggatcatgt	OIP5-AS1 3'	tttagctgtttcagacat
MDN1 3'	cctttgtagtaagagcaaca	OIP5-AS1 3'	acctgaatgtgctttgtga
MDN1 3'	cagcctaccatggacataaa	OIP5-AS1 3'	tcccaaagtattttagca
MDN1 3'	ctgcaaagccagcatattat	OIP5-AS1 3'	gtfaccattccactttatc
MDN1 3'	gcctcctataaggetacac	OIP5-AS1 3'	ttcaattctgaacctgga
MDN1 tiling	acacacactgcaagctgctc	OIP5-AS1 3'	accaaacatcacagtcacaa
MDN1 tiling	ctggagcagccaagttaatc	OIP5-AS1 3'	ggatatgacatctcacttca
MDN1 tiling	agagtgagcgtgaatgtg	OIP5-AS1 3'	tgctatcaagtaattgggga
MDN1 tiling	ccctgtcaagctgtgtaag	OIP5-AS1 3'	gttcttaactttactggct
MDN1 tiling	ttcacggttatcatccaaca	OIP5-AS1 3'	gccttagtggataatcgga
MDN1 tiling	tctgtgtttctgttactag	OIP5-AS1 3'	tgatgtctggttcccaaaa
MDN1 tiling	agttacactcaatgtggat	OIP5-AS1 3'	gatttagacttcatggaga
MDN1 tiling	ctcagtcacacgatatggc	OIP5-AS1 3'	agatacctattctgacttta
MDN1 tiling	ccatatttctgtaaaccggt	OIP5-AS1 3'	acctgaatactgtcagtaac
MDN1 tiling	taaatctcacggcttgtgc	OIP5-AS1 3'	tgacatatcacaagggaga
MDN1 tiling	attattctgtgtaggacag	OIP5-AS1 3'	tcctggggagaaaatattt
MDN1 tiling	tgcactgagtgcatagtctg	OIP5-AS1 3'	gtattaccagaatacctttc
MDN1 tiling	ccccaaaatctctgctttt	OIP5-AS1 3'	tgccaagactgttactgttt
MDN1 tiling	ctgttctaaaggattctga	OIP5-AS1 3'	gaaatgggtcgttttgtga
MDN1 tiling	aatgactgggtcaggagcaa	OIP5-AS1 3'	attctacaaggcagtaggt
MDN1 tiling	tcatctgcacacacttcatg	OIP5-AS1 3'	gtaaacacagtgagcaactc
MDN1 tiling	caactgcgtaagcttcacac	OIP5-AS1 3'	tgagaaataggaggacagc
MDN1 tiling	tcaaatgtgccatggctatg	OIP5-AS1 3'	acgttatacacaatgggtgc
MDN1 tiling	gcaggtactggacaattagt	OIP5-AS1 3'	aagcaagctgcctttgtaa
MDN1 tiling	aggctctgtctaaactcagc	OIP5-AS1 3'	acccccaaagatgcatagatt
MDN1 tiling	agccatttaactctgagcat	OIP5-AS1 3'	ccaacttttttaacagtcc
MDN1 tiling	gcggtatattctggctaaa	TUG1 5'	cactaaggcggcataaggag
MDN1 tiling	ggactagtgcatacaaaagt	TUG1 5'	acccccacacattgatagg
MDN1 tiling	actggcatcagacaccattc	TUG1 5'	ttgtgaagggtcccaaatga
MDN1 tiling	gttctaaacactgagcatgc	TUG1 5'	ggactcaaacagggtctcaa
MDN1 tiling	aaccaagtgagagtcctttg	TUG1 5'	agaaacagctcacatatccc
MDN1 tiling	ggcaaagggtccacattag	TUG1 5'	aacccccgaatatccattatg
MDN1 tiling	tccaaaacagacttgggtgc	TUG1 5'	aatagaagccaagcagggga
MDN1 tiling	gaggtgagcaactggcagag	TUG1 5'	ccccatggtgaaagaaaagg
MDN1 tiling	ttaccaacaaagtgggtgca	TUG1 5'	attgtaccatatgcatcagc
MDN1 tiling	tttagaaggctctgggttac	TUG1 5'	tcctaattgtagctgcttta
MDN1 tiling	cggaactgggtgtgactg	TUG1 5'	ggatgtacagaacacatcc



MDN1 tiling	acatgtctgaagagctgcag	TUG1 5'	gttgacgggccaaggataa
MDN1 tiling	ttctctgggctatgcgttc	TUG1 5'	accagtacaagcagcagata
MDN1 tiling	tagaagtcataagggccatc	TUG1 5'	tatggtcataagagtcaga
MDN1 tiling	tgctctggaacattgggat	TUG1 5'	atggatgacaacctggctg
MDN1 tiling	gcaacatcaaggtcatctgt	TUG1 5'	cctagacatgtaaagtagga
MDN1 tiling	aagtcgcatggaactctc	TUG1 5'	ctattcaccaccaaccacac
MDN1 tiling	ctgacaccactctggaattg	TUG1 5'	ctggcagcaccatgtaaaaa
MDN1 tiling	ttggcaagcgacgcagaag	TUG1 5'	cgtgcaccattaatagctg
MDN1 tiling	ggtgctagtctgcgttaag	TUG1 5'	tgagcccgttgctaaaagt
MDN1 tiling	aatgtgctgagaacctctg	TUG1 5'	aattccatgccaggctcagt
MDN1 tiling	cagctgactccaggtattg	TUG1 5'	aaaaacccaacatcttca
MDN1 tiling	caaaggtgatctgtttccg	TUG1 5'	ctactgattttgaggttccg
MDN1 tiling	cataatcttctgtgggctt	TUG1 5'	ttagctttgaaactctcca
MDN1 tiling	ttagatgtcctgattgcagt	TUG1 5'	agaacacaaggaggccaag
MDN1 tiling	cccttctgaaatgtatctc	TUG1 5'	tcctagtattacacttcaa
MDN1 tiling	tcgcccttaatatcagattt	TUG1 5'	gcaaaaactggcatcttga
MDN1 tiling	ccacctcatttcacatag	TUG1 5'	tttgttgataatggcctga
MDN1 tiling	ttcctgattgccatgtaag	TUG1 5'	tgagcaccactccacaaaac
MDN1 tiling	ggccaactgggcaatgaaat	TUG1 5'	atgtgtttgtttcacttgc
MDN1 tiling	ttttcctggtgtgcttctg	TUG1 5'	agcataactggctaacaatct
MDN1 tiling	gtaactctgccacatctcag	TUG1 5'	tcctcgcctttaggaaaag
MDN1 tiling	gtgaaagaggcgtgtaag	TUG1 5'	gtcatttctctggaagtgag
MDN1 tiling	gagcagctgcaaacatgttg	TUG1 5'	accaacacttttttctcc
MDN1 tiling	aactgatgttctgcgagagc	TUG1 5'	gaggtacatccggtttaat
MDN1 5' additional	atgactgtttagcggtcgat	TUG1 5'	tcaccacagcttaagtctt
MDN1 5' additional	ccaggtgaattttggccaa	TUG1 5'	ttctgctgaggaagcatct
MDN1 5' additional	cagttctcttattccaggt	TUG1 3'	gagtgacagggtcagcagag
MDN1 5' additional	gtttctctccagtaagttgg	TUG1 3'	gtttaggagtctatgctaca
MDN1 5' additional	gaactatcactccaagagt	TUG1 3'	cctcaatcagacttgaggtt
MDN1 5' additional	aacttctcaggtgctgtt	TUG1 3'	acttctcagctcaggagaagg
MDN1 5' additional	ctcaagggttggtctttgt	TUG1 3'	tttctgctcatctgccaaa
MDN1 5' additional	gggcaatcctattacaccaa	TUG1 3'	agtcaggatcatcagctttc
MDN1 5' additional	ctcagaaagcattgctgtga	TUG1 3'	ggatacagttttctgatctt
MDN1 5' additional	gctccaataactctgcca	TUG1 3'	gggtaatccatagggcttat
MDN1 5' additional	ttgtctgacacactgcaa	TUG1 3'	gttttactctgggtactca
MDN1 5' additional	atggtagagttttgccagt	TUG1 3'	ccagcagatcaataaggaag
MDN1 5' additional	cctgtaatgtgagccaagta	TUG1 3'	gccagaatatgatctggaag
MDN1 5' additional	attgacaacctcaaacggt	TUG1 3'	agaaaggccagccataccaa
MDN1 5' additional	gcaagtctgcagtatcactt	TUG1 3'	aatagacaagcagggtacct
MDN1 5' additional	atgtccaccggtttataac	TUG1 3'	aaaggcaggcaagagctgag

MDN1 5' additional	gtaaggtagccaaataagc	TUG1 3'	gtctaattgcagcaacatgt
MDN1 5' additional	aagagttcctcaaatgcctc	TUG1 3'	aattgactgtagtctcacg
MDN1 5' additional	gccccagaacgtaagttt	TUG1 3'	aaatcctgtgtattgggc
MDN1 5' additional	ctgtctgtaacaggctctgaa	TUG1 3'	agggtggggtgtactatt
MDN1 5' additional	ttagtctcaggagatcatgc	TUG1 3'	gaacattgagtcctagtggg
MDN1 5' additional	agcagactgtgtacatgct	TUG1 3'	aagttgctggtaaggagta
MDN1 5' additional	cactgtctttccatccttg	TUG1 3'	acatacaggaatagaggcct
MDN1 5' additional	ccaaatgcttcccatttctc	TUG1 3'	aggttccagggtgctgaaaaat
MDN1 5' additional	ttgggatggttgagtctaa	TUG1 3'	aactgctgattcctccag
PRPF8 5'	ctcgataaggaaacactccg	TUG1 3'	agagaaatggacgcggcttt
PRPF8 5'	caattgctgccattttcgag	TUG1 3'	actcatttctgcactactga
PRPF8 5'	acttccgcttttctcatag	TUG1 3'	tctgtgtgtactggtgaatc
PRPF8 5'	tggtctcgaatgatcttct	TUG1 3'	tgctaggttgaactggtaca
PRPF8 5'	aacttctgttggtcatgct	TUG1 3'	acagtggaaacttttctct
PRPF8 5'	catgttctccaggagtttga	TUG1 3'	ctgtgaggcaatttgagtca
PRPF8 5'	attgacgaaggaaatggctc	TUG1 3'	acaactagccttctacatca
PRPF8 5'	gtagacaggttcaatgacc	TUG1 3'	aactgtcctgctgatctgaa
PRPF8 5'	tttctcggcgcatcataat	TUG1 3'	agtggctatgagctgagag
PRPF8 5'	ggaaaaagcctccttctgaa	TUG1 3'	ccacagttcaacacaagca
PRPF8 5'	cggctcctcatcatcaaaag	TUG1 3'	gtccaatagcatatgttggga
PRPF8 5'	ggatgtgtcagcatagtc	TUG1 3'	cctcaagaagtctgtaatcc
PRPF8 5'	ggtcatagaaccagtccaac	TUG1 3'	atgagagataagtttctct
PRPF8 5'	tggtaaagtgagccatttac	TUG1 3'	gtttcttcttgggtataaa
PRPF8 5'	cggtagagagctgacatcat	TUG1 3'	ttgaatggtaacagctggca
PRPF8 5'	agtctgtcaggagctgatta	TUG1 3'	agcttaatctctgcttaaga
PRPF8 5'	gacgtaaagaaggccttcaa	PRPF8 3'	gtgacaatgatctgcttggg
PRPF8 5'	caggaatggcatattgagt	PRPF8 3'	gtgggtccagcatgcccttc
PRPF8 5'	gtctcgaacaagaggttcaa	PRPF8 3'	gggaagtcagtaagtgcac
PRPF8 5'	ctgccggatgataatctgt	PRPF8 3'	ctccgatccttctgatgaaa
PRPF8 5'	tcttactactagtcgggata	PRPF8 3'	cttgagacacgcctggaaag
PRPF8 5'	aagtagaaagctggcaagtc	PRPF8 3'	tgagatccccgaattttcc
PRPF8 5'	gggagctcaaatcctcatc	PRPF8 3'	ctggggctcagtggtttaa
PRPF8 5'	ccattggctgtattgtctgt	PRPF8 3'	catagaggttgaagagaacc
PRPF8 5'	cttaagcagcttctggtagg	PRPF8 3'	tgaatatgcttctgagccagt
PRPF8 5'	cttcttttgagccttagggg	PRPF8 3'	cgcagaatcaggatgagacg
PRPF8 5'	cagctttgtgactgaaaga	PRPF8 3'	atcgtttcacatgtaggg
PRPF8 5'	tttccacaggcttgaggttg	PRPF8 3'	gcttcaggatcacttttccc
PRPF8 5'	gtggaaagcattcccaaac	PRPF8 3'	cgacctgatccattctctg
PRPF8 5'	cagcttagtcaaacgcagaa	PRPF8 3'	caagatcagatccttgagct
PRPF8 5'	atactgcacgtgactatcca	PRPF8 3'	tgtttttcttcccgtagtca



MDN1 5' additional	acagcattctgagaagcaac	SunTagV4	acctcgttctcaagatgata
MDN1 5' additional	tcctattggtcctccaaca	SunTagV4	cggaaccttcttcaaacgc
MDN1 5' additional	cctgtcactgcagctaaata	SunTagV4	agttcttcgagagcagttcc
MDN1 5' additional	aagctggactttgagaagct	SunTagV4	gatcccttttfaatcgagc
MDN1 5' additional	acatctgtgcagcgatacat	SunTagV4	tgaaagtagttcctcaccac
MDN1 5' additional	atatcctccagaaggatcca	SunTagV4	cttcgttttcgaggtgtaa
MDN1 5' additional	aagagctctccattctccaa	SunTagV4	ccctgaacctttctttaatc
MDN1 5' additional	aaatccaggtgccatttca	SunTagV4	tactcagtaattcttccacc
MDN1 5' additional	caatttctccacagctcaa	SunTagV4	tttcgatagcaactcttcgc
MS2V5	tgattgtgaagtgtcgggtg	SunTagV4	ttttgagcctagcaacttc
MS2V5	tcacccttgtgtattgtac	SunTagV4	tttcgagagcaactcctcg
MS2V5	tgaatgtgtctggagggtg	SunTagV4	acctcattttccaagtggta
MS2V5	gcttctgtttgattggattt	SunTagV4	tttgctcaataactcctcgc
MS2V5	gatggtgattcctgtttgta	SunTagV4	cgcgacttcgttctctaaat
MS2V5	gtatattgcacaggggaatcc	SunTagV4	ttcgataagagttcttcgcc
MS2V5	gatattcgggagcgtgatc	SunTagV4	ctcattttcgaggtgtagt
MS2V5	acgcactgaattcgaagacc	SunTagV4	agtggtagttcttgctcaag
MS2V5	attcgactctgattggctgc	SunTagV4	ttcaatctcgcgacctcatt
MS2V5	ctcttcgcgaaagtcgactt	SunTagV4	atttctgctgagcaattcct
MS2V5	taagaatggcgcgaaagctg	SunTagV4	cgacttcgttctccaatga
MS2V5	gtaggggagagtggtgttg	SunTagV4	cgacttcattttccaagtgg
MS2V5	caggaacgctgatgctgttc	SunTagV4	ttgctcaataactcttcgcc
MS2V5	tttcttgagttgggtactg	SunTagV4	ttcgttctccaagtggtaat
MS2V5	tgatgctgcatggggacata	SunTagV4	agttcttcgataagagctcc
MS2V5	ttggggatgtattcttgggg	SunTagV4	gcgacttcattctctaagtg
MS2V5	ttggtgctcggatgtgattt	SunTagV4	ttcttctcaagagctcttc
MS2V5	aagaacaacactccgagcc	SunTagV4	cacctcattttccaagtgg
MS2V5	atggagggtttgtccagttg	SunTagV4	ttagatagtaactcttcccc
MS2V5	tttcttgttgggtgagagt	SunTagV4	cctcgttctcgagatgataa
MS2V5	ctgatgctgcttcgagaaga	SunTagV4	gatagttcttcgacaggagt
MS2V5	gtatgctcagtgtttcgaa	SunTagV4	ccttttaagtcttgcacc
MS2V5	gatcgtccaccaagaaata	SunTagV4	ttactgagtagttctcacc
MS2V5	aattcgtgagagcatgggtg	SunTagV4	ttcgtttccaggtggtaat
MS2V5	tcgtattggacgtggaacga	SunTagV4	tctgatcctttctcaaac
MS2V5	tcgtgatcccgaaggttaag	SunTagV4	cttttgagagcagttcttcg
MS2V5	atcgtgcatgcttgaatgtc	SunTagV4	gcaacctcattttccaaatg
MS2V5	gttgagacttgggagcatg	SunTagV4	tgccactcccttttttaa
MS2V5	tgaaccatttggtagtttc	SunTagV4	tttcgacagaagttcctcac
MS2V5	tttaggttaggagtggttc	SunTagV4	gctacttcattctcgagatg
MS2V5	ttgccagtttggggaaga	SunTagV4	gagccagaaccttttaag
MS2V5	tttggtatgttgaatgggc		
MS2V5	gatgctgtaccagtaattgt		
MS2V5	tagtagtgagagatgtgggc		
MS2V5	tgctgaacggtttggtttt		
MS2V5	ttgattttccgtgtgtacc		
MS2V5	gtcttctgatttgaaac		
MS2V5	ttgcgctggacgaaagcgtg		
MS2V5	ccgtcggatgttttcgtaa		

MS2V5	ggttgtaagtttggggtg		
MS2V5	ctgaggtgttgatgtacgg		

**Table S3:** Probe and antibody combinations used

<b>Experiment</b>	<b>Combination of probes/antibodies and dyes used (From Table S1)</b>
MDN1 5'-3'	MDN1 5' -Cy5 MDN1 3' - Dy550
MDN1 5'-tiling-3'	MDN1 5'+ MDN1 5' additional – Dy488 MDN1 tiling – Cy5 MDN 3' – Dy550
MDN1 5'-middle-3'	MDN1 5'+ MDN1 5' additional – Dy488 MDN1 middle – Cy5 MDN 3' – Dy550
PRPF8 5'-3'	PRPF8 5' -Cy5 PRPF8 3' - Cy3
POLA1 5'-3'	POLA1 5' -Cy3 POLA1 3' - Cy5
TUG1 5'-3'	TUG1 5' -Cy5 TUG1 3' - Cy3
OIP5-AS1 5'-3'	OIP5-AS1 5' -Cy5 OIP5-AS1 3' - Cy3
MDN1 tiling-3'	MDN1 tiling + MDN1 tiling additional– Cy5 MDN1 3'– Dy550
MDN1 5'-3'-dT	MDN1 5' -Cy5 MDN1 3' - Dy550 dT – Cy2
MDN1 tiling-3'-dT	MDN1 tiling + MDN1 tiling additional– Cy5 MDN1 3'– Dy550 dT- Cy2
PRPF8 5'-3'-dT	PRPF8 5' -Cy5 PRPF8 3' - Cy3 dT – Cy2
POLA1 5'-3'-dT	POLA1 5' -Cy3 POLA1 3' - Cy5 dT – Cy2
TUG1 5'-3'-dT	TUG1 5' -Cy5 TUG1 3' - Cy3 dT – Cy2
OIP5-AS1 5'-3'-dT	OIP5-AS1 5' -Cy5 OIP5-AS1 3' - Cy3 dT – Cy2
SINAPs 5'-3'	SuntagV4 5' – Quasar 570 MS2v5 3' – Cy5 Chicken anti-GFP Antibody Goat-Anti Chicken Alexa 488

## References

1. Bin Wu, C. Eliscovich, Y. J. Yoon, R. H. Singer, Translation dynamics of single mRNAs in live cells and neurons. *Science*, aaf1084 (2016).
2. D. Rakheja *et al.*, Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours. *Nat Comms.* **2**, 4802 (2014).
3. S. Rahman, D. Zenklusen, in *Imaging Gene Expression* (Humana Press, Totowa, NJ, 2013), vol. 1042 of *Methods in Molecular Biology*, pp. 33–46.
4. S. Rahman *et al.*, Single-cell profiling reveals that eRNA accumulation at enhancer-promoter loops is not required to sustain transcription. *Nucleic Acids Res.* **45**, 3017–3030 (2017).
5. R. Thompson, D. Larson, W. Webb, Precise nanometer localization analysis for individual fluorescent probes. *Biophys J.* **82**, 2775–2783 (2002).
6. D. Zenklusen, D. R. Larson, R. H. Singer, Single-RNA counting reveals alternative modes of gene expression in yeast. *Nat Struct Mol Biol.* **15**, 1263–1271 (2008).
7. T. Lionnet *et al.*, A transgenic mouse for in vivo detection of endogenous labeled mRNA. *Nat Methods* (2011), doi:doi:10.1038/nmeth.1551.
8. C. Eliscovich, S. M. Shenoy, R. H. Singer, Imaging mRNA and protein interactions within neurons. *Proceedings of the National Academy of Sciences*, 201621440 (2017).
9. F. Mueller *et al.*, FISH-quant: automatic counting of transcripts in 3D FISH images. *Nat Methods.* **10**, 277–278 (2013).